Nathan Sepeda
Director of Data & Analytics
Data updated
Research Footprint
Nathan Sepeda appears in 17 tracked papers (2020–2026), most studied alongside Psilocybin, 5-MeO-DMT and Ibogaine, across Depressive Disorders, Anxiety Disorders and Healthy Volunteers.
Most-cited paper: Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder (1236 citations).
Frequent co-authors: Alan Davis, Frederick Barrett and Roland Griffiths.
Background & Research
Nathan D. Sepeda is a clinical researcher specialising in clinical trials and outcome measurement within psychedelic medicine. He has been a frequent collaborator on multi‑centre and single‑site investigations into the psychological and neurofunctional effects of classic and atypical hallucinogens, contributing to work on psilocybin‑assisted therapy for major depressive disorder, healthy‑volunteer pharmacology studies, and longer‑term follow‑up safety and efficacy assessments. Sepeda's work spans experimental double‑blind comparisons, prospective 12‑month outcome monitoring, and targeted studies of spiritual and religious experience in diverse populations.
His research emphasis is on quantifying experience‑dependent and enduring psychological changes after psychedelic administration and identifying predictors of treatment response. Sepeda has co‑authored pivotal publications from programmes affiliated with major psychedelic research centres and applies interdisciplinary methods — clinical trial design, standardised psychological measures and neurobehavioural assessments — to clarify therapeutic potential, adverse effects and mechanisms of change in psychedelic‑assisted interventions.
Key Impact
Notable for his contributions to clinical and experimental studies of psilocybin-assisted interventions, including trials of major depressive disorder and investigations of enduring psychological and neurofunctional effects.
Collaboration Network
30 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Nathan Sepeda is associated with.
Johns Hopkins Center for Psychedelic and Consciousness Research
A research center within Johns Hopkins University (School of Medicine) that conducts scientific studies on psychedelic compounds, their effects on brain function and consciousness, and their therapeutic potential for mental health conditions.
View stakeholder →Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →